Enanta Pharmaceuticals Advances Zelicapavir Clinical Development for RSV Treatment

Enanta Pharmaceuticals, Inc. announced progress in its zelicapavir clinical development program for respiratory syncytial virus (RSV). The company plans to initiate a registrational Phase 2b/3 clinical trial for high-risk adults and a Phase 2b trial for pediatric patients. This advancement marks a significant step towards potentially bringing a new treatment option to market for RSV.